Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Buy Rating Affirmed for Immunic, Inc. on Promising MS Drug Developments and Favorable Market Position
Analyst William Wood from B.Riley Financial reiterated a Buy rating on Immunic (IMUX – Research Report) and keeping the price target at ...
Le Lézard21d
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic ? ? In Addition to Post COVID Readouts, ...
Frontiers24d
Development and validation of a nomogram for predicting advanced liver fibrosis in patients with chronic hepatitis B
The First Affiliated Hospital of Anhui Medical University, Hefei, China Background: The progression of chronic hepatitis B (CHB) to liver fibrosis and even cirrhosis is often unknown to patients, but ...
Investing29d
B.Riley sees upside in Immunic stock, initiating coverage with confidence in MS treatment potential
The firm believes that vido's mechanism, which includes dihydroorotate dehydrogenase (DHODH) inhibition along with Nurr1 activation, offers additional benefits. Nurr1 activation is noted for its ...
eLife2y
Developmental single-cell transcriptomics of hypothalamic POMC neurons reveal the genetic trajectories of multiple neuropeptidergic phenotypes
This study investigates the developmental origins of functionally distinct neuronal populations in the arcuate nucleus of the hypothalamus. This study reports the transcriptional program of develop of ...